Choi S Y, Pang L, Kern P A, Kayden H J, Curtiss L K, Vanni-Reyes T M, Goldberg I J
Department of Medicine, Columbia University College of Physicians & Surgeons, New York, NY, USA.
J Lipid Res. 1997 Jan;38(1):77-85.
We have shown previously that the activity of lipoprotein lipase (LPL), the major enzyme responsible for hydrolysis of triglyceride contained in circulating lipoproteins, is associated with lipoproteins in postheparin plasma. In other studies, microtiter plate assays showed that LPL interaction with low density lipoprotein (LDL) and very low density lipoprotein (VLDL) was decreased by antibodies to apolipoprotein (apo)B. To test whether antibodies to apoB affected LPL-LDL association in solution, two types of assays were performed, gel filtration and coprecipitation. First we showed that LPL activity and immunoreactive mass co-eluted during gel filtration of normal postheparin plasma, approximately with the peak of low density lipoproteins. Then LPL was used for gel filtration studies in the presence and absence of LDL and anti-apoB monoclonal antibodies. LPL association with LDL was diminished by antibodies to the amino-terminal region of apoB; antibodies to the carboxyl-terminal LDL receptor binding region of apoB were less effective. LDL binding to LPL containing heparin-agarose was also disrupted by the amino-terminal antibodies to apoB. To determine the LPL-lipoprotein association in situations in which the distribution of plasma lipoproteins was altered, we studied plasma from two types of subjects with dyslipidemias. The addition of 125I-labeled LPL to type 1 postheparin plasma produced two peaks of radioactivity, one peak eluted in the void volume of the column (with the chylomicrons) and a second peak eluted just prior to the normal elution of low density lipoproteins. In postheparin plasma from an abetalipoproteinemic subject, LPL eluted with HDL. We conclude that LPL associates primarily with apoB-containing lipoproteins. The reason for this appears to be that LPL interacts with the apoB.
我们之前已经表明,脂蛋白脂肪酶(LPL)是负责水解循环脂蛋白中甘油三酯的主要酶,其活性与肝素后血浆中的脂蛋白相关。在其他研究中,微量滴定板分析表明,抗载脂蛋白(apo)B抗体可降低LPL与低密度脂蛋白(LDL)和极低密度脂蛋白(VLDL)的相互作用。为了测试抗apoB抗体是否会影响溶液中LPL-LDL的结合,我们进行了两种类型的分析,即凝胶过滤和共沉淀。首先,我们发现在正常肝素后血浆的凝胶过滤过程中,LPL活性和免疫反应性物质共同洗脱,大致与低密度脂蛋白的峰值一致。然后,在有或没有LDL和抗apoB单克隆抗体的情况下,使用LPL进行凝胶过滤研究。apoB氨基末端区域的抗体可减少LPL与LDL的结合;apoB羧基末端LDL受体结合区域的抗体效果较差。apoB的氨基末端抗体也会破坏LDL与含肝素琼脂糖的LPL的结合。为了确定血浆脂蛋白分布改变情况下的LPL-脂蛋白结合情况,我们研究了两种血脂异常患者的血浆。将125I标记的LPL添加到1型肝素后血浆中产生了两个放射性峰值,一个峰值在柱的空体积中洗脱(与乳糜微粒一起),另一个峰值在低密度脂蛋白正常洗脱之前洗脱。在无β脂蛋白血症患者的肝素后血浆中,LPL与HDL一起洗脱。我们得出结论,LPL主要与含apoB的脂蛋白结合。其原因似乎是LPL与apoB相互作用。